NCT07682961
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 148 words Show 4 more changesShow less
- Primary endpoints: details revised at 1 of 1 entry
- Enrollment increased: 590 → 850 participants
- Trial sites expanded: 19 → 61 locations
- Secondary endpoints: details revised at 3 of 12 entries
- Minor Trial sites expanded: 3 → 19 locationsv3
- Notable Recruitment opened
- Trial sites expanded: 0 → 3 locations
- Start date changed from estimate of Jul 2026 to Jul 14, 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (12)
Show 7 moreShow less
Arms and interventions
Participants meeting susceptibility criteria will receive oral LEN 600 mg, subcutaneous (SC) LEN 927 mg, and intravenously (IV) infusions of TAB and ZAB on Day 1. Participants will self-administer oral LEN 600 mg on Day 2. Every 26 weeks, participants will receive SC LEN and IV infusions of TAB and ZAB up to Week 92. After Week 92, eligible participants will have an option to continue LEN + TAB + ZAB in the extension phase, until completion of the extension phase, permanently discontinuing the extension phase or the extension is discontinued at the sponsor's sole discretion, whichever occurs first.
Participants who meet susceptibility criteria will discontinue their baseline oral antiretroviral therapy (ART) and will receive intramuscular (IM) CAB 600 mg + RPV 900 mg on Day 1, Week 4 and then every 8 weeks for up to 92 weeks. After Week 92, eligible participants will have an option to continue LEN + TAB + ZAB in the extension phase, until completion of the extension phase, permanently discounting the extension phase or the extension is discontinued at the sponsor's sole discretion, whichever occurs first.
Drugs: Lenacapavir, Lenacapavir Tablet, Teropavimab, Zinlirvimab, Cabotegravir, Rilpivirine
Sites
61 sites in 8 countries
United States 37, Germany 7, South Korea 4, Australia 3, Japan 3, Switzerland 3, Taiwan 3, Spain 1